STOK
NASDAQ · Biotechnology
Stoke Therapeutics Inc
$26.60
+0.53 (+2.03%)
Open$26.41
Previous Close$26.07
Day High$26.73
Day Low$25.96
52W High$40.22
52W Low$20.32
Volume—
Avg Volume1.56M
Market Cap1.73B
P/E Ratio—
EPS$-3.36
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+88.6% upside
Current
$26.60
$26.60
Target
$50.17
$50.17
$29.72
$50.17 avg
$68.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 202.39M | 323.22M | 315.22M |
| Net Income | -7,558,135 | -37,471,003 | -43,595,472 |
| Profit Margin | -3.7% | -11.6% | -13.8% |
| EBITDA | -20,653,271 | -52,091,948 | -53,358,586 |
| Free Cash Flow | — | -52,998,459 | -42,607,892 |
| Rev Growth | +145.9% | +14.4% | -1.8% |
| Debt/Equity | — | 0.58 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |